Physician profile
Daniel C Murphy
NPI 1487981403
$8,941.29
in general payments reported to CMS, 2019-2025
37 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,035 · 2022: $2,044 · 2023: $2,523 · 2024: $1,798 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,688 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,688.25 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,371.92 | 2021-2025 | |
| Janssen Biotech, INC. | $1,038.16 | 2021-2025 | Stelara, Simponi Aria, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $641.51 | 2021-2024 | Xifaxan |
| Pfizer INC. | $404.34 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $397.29 | 2021-2025 | Entyvio, Trintellix |
| Amgen INC. | $376.69 | 2024 | Otezla, Repatha, Prolia |
| Gilead Sciences, INC. | $262.02 | 2021-2023 | Epclusa |
| Janssen Scientific Affairs, LLC | $250.55 | 2022-2023 | Stelara |
| Celgene Corporation | $208.34 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $194.19 | 2021-2023 | Injectafer |
| Genzyme Corporation | $160.99 | 2022-2023 | |
| Madrigal Pharmaceuticals | $147.56 | 2025 | Rezdiffra |
| Axsome Therapeutics, INC. | $142.74 | 2023-2024 | Auvelity |
| Aimmune Therapeutics, INC. | $135.50 | 2024 | |
| Novartis Pharmaceuticals Corporation | $104.35 | 2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $101.58 | 2024 | Veozah |
| Lilly USA, LLC | $101.25 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Redhill Biopharma INC. | $85.42 | 2021-2023 | Aemcolo, Talicia |
| Qol Medical, LLC | $83.73 | 2022-2023 | Sucraid |
| Sumitomo Pharma America, INC. | $64.25 | 2024 | Gemtesa |
| Novo Nordisk INC | $62.57 | 2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $58.02 | 2024 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $57.58 | 2023 | Ocaliva |
| Astrazeneca Pharmaceuticals Lp | $57.52 | 2023-2024 | Andexxa, Farxiga |
| Corium, LLC | $45.12 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $42.97 | 2022 | |
| Alnylam Pharmaceuticals INC. | $42.21 | 2021-2022 | |
| Glaxosmithkline, LLC. | $41.81 | 2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $39.17 | 2024 | Xarelto |
| Esperion Therapeutics, INC. | $38.85 | 2024 | Nexletol |
| Mylan Institutional INC. | $38.68 | 2023 | Hulio |
| Ironwood Pharmaceuticals, INC | $35.09 | 2021 | |
| Ardelyx, INC. | $29.25 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $28.26 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.77 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $15.30 | 2021 | |
| Vivus LLC | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.